Lipella Pharmaceuticals Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jonathan Kaufman
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7800 Susquehanna St. Pittsburgh PA United States of America 15208
- IPO Date
- Dec 19, 2022
- CIK
- 0001347242
- Website
- lipella.com
- Similar Companies
- Business
- Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company specializing in the development of targeted drug delivery systems through its proprietary Liposome Drug Delivery technologies. The company’s core products and services include designing, developing, and commercializing therapeutics that enhance the delivery and efficacy of drugs using liposomal encapsulation techniques. These products primarily focus on oncology, autoimmune diseases, and infectious diseases, offering pharmaceutical partners advanced formulation solutions. Lipella operates primarily in the United States and is headquartered in Boston, Massachusetts. Founded in 2003, the company leverages its proprietary Liposomal technology platform across various therapeutic areas to improve pharmacokinetics and reduce toxicity. In recent developments over the last 1-2 years, Lipella Pharmaceuticals has expanded its strategic alliances and research collaborations with multiple pharmaceutical companies to enhance its pipeline and commercialization capabilities. The company has also advanced its clinical program with the launch of new trials for its lead product candidates targeting cancer and inflammatory diseases. Lipella continues to strengthen its technology platform and grow its operational footprint to accelerate drug development and delivery partnerships, although there have been no publicized name changes or major acquisitions reported during this period. These strategic expansions and ongoing research underscore Lipella’s commitment to innovation in drug delivery solutions. Lipella Pharmaceuticals serves the biotechnology and pharmaceutical industry segments with its novel drug delivery technology designed for specialized markets requiring precision medicine approaches. Its target customers include pharmaceutical companies seeking enhanced drug formulations, clinical trial sponsors, and research institutions. The company’s geographic operations are primarily focused in North America with collaborative research efforts potentially extending globally through partnerships. Overall, Lipella Pharmaceuticals offers proprietary liposomal drug delivery formulations; pharmaceutical research and development services; and clinical-stage therapeutic candidates in oncology, autoimmune, and infectious diseases. The company was established in 2003 and maintains its headquarters in Boston, Massachusetts, positioning itself as a technology-driven player in the pharmaceutical innovation ecosystem. Recent efforts emphasize clinical advancement and collaboration to broaden product applications and improve patient outcomes.
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
Lipella Pharmaceuticals (NASDAQ:LIPO) Trading Down 14.8% – Here’s What Happened
Lipella Pharmaceuticals (NASDAQ:LIPO) Stock Price Up 4.2% – Still a Buy?
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
Spartan Capital Securities, LLC Announces Key February Transactions
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement